Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TScan Therapeutics, Inc.TCRX · Entity 7255 | See Remarks | January 20, 2026 | January 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TScan Therapeutics, Inc.
Report date January 20, 2026 · Filed January 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2036-01-20 | Direct | 100,000 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 22, 2026 22:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001193125-26-019702 · ownership.xml · derivative · entry 1 Dworak Leiden · CIK 0001986012 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 12, 2024 Filed Feb 11, 2025 22:54 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 46,875 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000950170-25-018130 · ownership.xml · derivative · entry 1 Dworak Leiden · CIK 0001986012 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Voting Common Stock · 46,875 shares Expires 2034-01-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| July 21, 2023 Filed Jul 24, 2023 23:39 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000950170-23-034156 · ownership.xml · derivative · entry 1 Dworak Leiden · CIK 0001986012 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Voting Common Stock · 25,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of July 21, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.